Financiere Hoche Bains-Les-Bains
EEURONEXT:MLHBB65.00
EUR
0.00
(0.00%)
ISIN
FR0000051302
Return %
Stock
S&P 500
1Y
8.33
13.14
3Y
20.37
80.78
5Y
38.30
67.74
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Quarterly Revenue
EUR
•
in mil. unless spec.Quarterly Earnings Per Share
EUR
•
in mil. unless spec.Quarterly Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- Sector
- Finance
- Industry
- Investment banks/Brokers
- Address
- 10 place Vendome Paris France 75001
- IPO Date
- Jan 3, 2000
- Website
- sfhbb.fr
- Similar Companies
- Business
- Financiere Hoche Bains-Les-Bains S.A. Financiere Hoche Bains-Les-Bains SA is a France-based holding company engaged in the management of securities, corporate rights, and equity stakes in various types of companies; it provides portfolio management services, investment holding activities, and participation in strategic investments across financial and other sectors. The company operates primarily from its headquarters at 10 Place Vendôme, 75001 Paris, France, with a registered capital of €1,123,900 and listing on Euronext Paris under the ticker MLHBB.PA; it was founded in 1955 and is governed by a board of directors chaired by Jacques Colignon, who also serves as CEO. Its activities fall within the asset management and investment services segment, targeting corporate clients and investment opportunities in Europe, with a focus on transferable securities and equity participations. In recent developments, the company participated in a capital increase for Temisis, a biotechnology firm developing plant-based biomolecules, acquiring a 1.64% stake in February 2024 as part of a funding round valued at €45 million pre-money, with a second tranche planned for July 2024 to support clinical development of an anti-psoriasis drug candidate. Previously, in October 2022, Financiere Hoche Bains-Les-Bains completed the acquisition of Cast Switzerland, expanding its portfolio of holdings. Additionally, the company appointed Steve Gentili and Michel Vuilleumier as new board members during its June 2023 annual general meeting, strengthening its governance structure. These moves reflect ongoing strategic investments in biotech and international assets, alongside routine financial reporting with audited accounts released annually through 2023 showing stable equity around €1.9 million.